Resolving the dark side of therapy-driven cancer cell death

In this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonavita, Eduardo, Pelly, Victoria S., Zelenay, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2018
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748866/
https://www.ncbi.nlm.nih.gov/pubmed/29263217
http://dx.doi.org/10.1084/jem.20172044
_version_ 1783289491540148224
author Bonavita, Eduardo
Pelly, Victoria S.
Zelenay, Santiago
author_facet Bonavita, Eduardo
Pelly, Victoria S.
Zelenay, Santiago
author_sort Bonavita, Eduardo
collection PubMed
description In this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, counteract this effect, representing an attractive target for therapeutic intervention.
format Online
Article
Text
id pubmed-5748866
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-57488662018-07-02 Resolving the dark side of therapy-driven cancer cell death Bonavita, Eduardo Pelly, Victoria S. Zelenay, Santiago J Exp Med News In this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, counteract this effect, representing an attractive target for therapeutic intervention. The Rockefeller University Press 2018-01-02 /pmc/articles/PMC5748866/ /pubmed/29263217 http://dx.doi.org/10.1084/jem.20172044 Text en © 2018 Bonavita et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle News
Bonavita, Eduardo
Pelly, Victoria S.
Zelenay, Santiago
Resolving the dark side of therapy-driven cancer cell death
title Resolving the dark side of therapy-driven cancer cell death
title_full Resolving the dark side of therapy-driven cancer cell death
title_fullStr Resolving the dark side of therapy-driven cancer cell death
title_full_unstemmed Resolving the dark side of therapy-driven cancer cell death
title_short Resolving the dark side of therapy-driven cancer cell death
title_sort resolving the dark side of therapy-driven cancer cell death
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748866/
https://www.ncbi.nlm.nih.gov/pubmed/29263217
http://dx.doi.org/10.1084/jem.20172044
work_keys_str_mv AT bonavitaeduardo resolvingthedarksideoftherapydrivencancercelldeath
AT pellyvictorias resolvingthedarksideoftherapydrivencancercelldeath
AT zelenaysantiago resolvingthedarksideoftherapydrivencancercelldeath

Ejemplares similares